SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

Reports that Advent International and Stripe have abandoned their pursuit of PayPal are removing the takeover premium and driving heavy selling. Traders are divided between viewing the drop as an overreaction to a lowball bid and arguing that PayPals standalone business faces meaningful competitive and execution risks.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Federal Reserve Chair Kevin Warshs Jackson Hole speech is driving attention, with traders parsing his warnings that inflation remains elevated and rate hikes may return while criticizing the lack of clear forward guidance. Despite the hawkish tone and higher September hike expectations, SPY remained resilient, fueling debate over whether markets are dismissing the speech or positioning for further volatility.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

A post-earnings selloff is driving attention after Marvell delivered a modest beat and raised its multi-year outlook, but investors focused on gross-margin pressure, elevated valuation, and the fact that much of the Google AI-chip opportunity may not materially boost revenue until later years. Traders are split between viewing the decline as an overreaction and buying opportunity versus arguing that expectations were too high and the stock remains overvalued.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

A quarterly earnings miss and an unclear outlook sparked a sharp selloff, with traders focused on heavy planned AI-infrastructure spending, potential dilution, and managements failure to identify the new frontier-AI customer or provide detailed guidance. Bulls argue the reaction overlooks IRENs accelerating AI Cloud transition, contracted capacity, and Microsoft-related deployments, while skeptics question execution, profitability, and financing needs.

Affirm Holdings, Inc. operates a platform for digital and mobile-first commerce. Its platform consists of three core elements: a point-of-sale payment solution for consumers, merchant commerce solutions, and a consumer-focused app. The company was founded by Max R. Levchin in 2012 and is headquartered in San Francisco, CA.

Affirm Holdings Inc - Ordinary Shares - Class A

Affirm Holdings Inc

A strong fiscal Q4 earnings beat and above-consensus outlook have driven attention toward Affirm, with traders emphasizing accelerating growth, profitability, and merchant adoption. The bullish reaction is tempered by repeated post-earnings selloffs and debate over one-time profit benefits, valuation, and rising credit or delinquency risk.

LightPath Technologies, Inc. engages in the design, development, manufacture, and distribution of optical and infrared components. Its products include molded glass and assemblies, infrared molded lenses, diamond turned, conventional ground and polished ground lenses and assemblies, and collimator assemblies, which are used in applications involving light detection and ranging technology. The firm supports a range of customers in the field of industrial, laser, defense, medical, telecommunications, and instrumentation. The company was founded in1985 and is headquartered in Orlando, FL.

Lightpath Technologies, Inc. - Ordinary Shares - Class A

The sharp selloff is being attributed to Army news widening the search for competitors on the NGSRI interceptor program, which traders fear could delay down-selection and reduce LightPaths potential opportunity. Others argue the notice does not change the targeted production timeline or confirm that LightPath has lost its position, calling the reaction headline-driven and excessive.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

Treasury bond buybacks and expectations around the Federal Reserves Jackson Hole messaging are driving attention, with traders viewing falling yields, dollar debasement concerns and fiscal stress as potential support for silver. The community is split between a bullish technical-breakout/short-squeeze thesis and warnings that SLV remains near resistance and could consolidate or pull back.

CrowdStrike Holdings, Inc. provides cybersecurity products and services to stop breaches. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, Zero Trust identity protection, and log management. CrowdStrike serves customers worldwide. The company was founded by George P. Kurtz, Gregg Marston, and Dmitri Alperovitch on November 7, 2011 and is headquartered in Austin, TX.

Crowdstrike Holdings Inc - Ordinary Shares - Class A

Crowdstrike Holdings Inc

A strong fiscal second-quarter report, record recurring-revenue additions, and a raised full-year outlook tied to accelerating AI-driven cybersecurity demand sparked a sharp rally and multiple analyst target increases. The subsequent selloff has shifted the debate toward profit-taking, options-driven volatility, and whether CrowdStrikes elevated valuation is justified, with traders divided between dip buyers and short sellers.

First Majestic Silver Corp. engages in the production, development, exploration, and acquisition of mineral properties, with a focus on silver and gold production in North America. It owns and operates producing mines in Mexico, including the Santa Elena Silver & Gold Mine, the Los Gatos Silver Mine, the San Dimas Silver & Gold Mine, and the La Encantada Silver Mine. It also owns the Jerritt Canyon Gold Mine in Nevada, USA, which is currently in the process of restarting. The company was founded by Keith Neumeyer on September 26, 1979 and is headquartered in Vancouver, Canada.

First Majestic Silver Corporation

First Majestic Silver investors are closely watching technical levels and potential breakout signals amid surging industrial demand for silver, while navigating persistent volatility and broader market uncertainty.

Rubrik, Inc. engages in the provision of cloud data management solutions. Its solutions include backup and recovery, VM backup, Microsoft 365, ransom ware recovery, database backup, cloud solutions, and Polaris sonar. Rubrik products include data protection, data threat analytics, data security posture and cyber recovery. The company was founded by Bipul Sinha, Arvind Jain, Soham Mazumdar, and Arvind Nithrakashyap in December 2013 and is headquartered in Palo Alto, CA.

Rubrik Inc. - Ordinary Shares - Class A

Rubrik Inc. - Class A

A strong quarterly earnings beat and raised full-year guidance has drawn attention, but shares sold off sharply after a sizable pre-earnings rally. Traders are split between viewing the decline as profit-taking and options-driven pressure versus concerns about decelerating cloud growth, stock-based compensation, and elevated expectations.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SRPT On Track For Best Week In 5 Months Ahead Of Late-2026 Clinical Data — Retail Eyes ‘Monumental Comeback’

Anticipation of Sareptas FSHD and DM1 clinical readouts, alongside a setback for rival Capricors DMD therapy, is supporting a rebound in SRPT. Traders are debating whether the sharp move reflects short covering and heavy options activity or unconfirmed buyout and news-leak speculation.

The move appears tied to renewed anticipation of Sareptas upcoming facioscapulohumeral and myotonic dystrophy clinical data, alongside rival Capricors delayed Deramiocel FDA decision, which could reduce near-term competition in Duchenne muscular dystrophy. Elevated volume and heavy short interest may have amplified the reaction, while buyout and news-leak claims remain unconfirmed.

Equity

Investors are now awaiting extra data from Sarepta’s mid-stage studies in two muscle diseases, facioscapulohumeral muscular dystrophy and myotonic dystrophy.


KROS $20M Takeda Milestone Adds Cash but Revenue Visibility Stays Weak

Keros gets a $20M Takeda milestone, boosting cash and flexibility, but weak revenue visibility keeps collaboration income in focus.

Should You Buy KROS Stock as Pipeline Promise Meets Revenue Risk?

Keros' rinvatercept pipeline offers upside, but zero quarterly revenue, clinical risk and a premium valuation make the stock a cautious bet.

Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (KSF), announces that KSF has commenced an investigation into Sarepta Therapeutics, Inc. (NasdaqGS: SRPT) (Sarepta or the Company).Sarepta is a biopharmaceutical company focused on...

Sarepta's Q2 Earnings & Sales Beat Estimates, '26 Outlook Updated

SRPT beat Q2 earnings and revenue estimates despite weaker Elevidys sales, while narrowing its 2026 product revenue outlook and tightening expense guidance.

Sarepta Therapeutics (SRPT) Q2 Earnings and Revenues Surpass Estimates

Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of +10.35% and +12.85%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Compared to Estimates, Sarepta Therapeutics (SRPT) Q2 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Sarepta Therapeutics (SRPT) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the second quarter of 2026. As I begin my tenure as CEO, I am excited by the strength of Sarepta's foundation, the impact our therapies are having for patients...

ANI Pharmaceuticals (ANIP) Reports Next Week: Wall Street Expects Earnings Growth

ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on July 28, 2026, that were previously approved by its Board of Directors under Sareptas 2024 Employment Commencement Incentive Plan, as amended, as a material inducement to...

• Reported GAAP EPS of -$0.05 down -102.49% YoY
• Reported revenue of $401.25M down -34.34% YoY
• Sarepta Therapeutics narrowed its 2026 total net product revenue guidance to $1.2-$1.3 billion and narrowed combined non-GAAP R&D and SG&A expense guidance to $800.0-$850.0 million for the full year.

Sarepta Therapeutics experienced a 34% revenue decline due to lower ELEVIDYS sales, incurred a $39 million litigation charge, and faces ongoing regulatory and commercial adoption risks for its product portfolio.

Sarepta Therapeutics achieved quarterly operating profitability, appointed a new CEO with extensive industry experience, and strengthened its financial position with a $197 million increase in cash and investment holdings.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Extremely Bullish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

The S&P 500 ($SPY) is headed towards a positive week. What do you think the index's return will look like next week? Vote and explain your reasoning in the comments.

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Stocktwits

Stocktwits Polls

Large-volume options activity involving January 2027 call spreads suggests smart money is positioning for future data readouts.

Traders are closely monitoring massive short interest and unexpected volatility, hoping for a sharp rally to trap bears.

Investors are awaiting clinical trial catalysts for the siRNA and FSHD programs as the primary drivers for a potential share price re-rate.

Speculation remains constant about potential M&A interest from major pharma companies as the company undergoes internal management changes.

Feed

News

Sentiment

Earnings

Fundamentals

Info

SRPT Sarepta Therapeutics Inc

Fundamentals

Connect Stocktwits to ChatGPT

Latest SRPT News